Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (31-40 of 179) with videos related to

Pageof 18
Sort By:
Blood|May 3, 2002
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantationEduardo Olavarria, Charles Craddock, Francesco Dazzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2023
Novel Clinical Trial Designs with Dose Optimization to Improve Long-term OutcomesPeter F Thall, Yong Zang, Andrew G Chapple, et al.
Haematologica|September 10, 2002
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerationsDavid Marin, Sarah Marktel, Marco Bua, et al.
British Journal of Haematology|April 13, 2007
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remissionJiri Pavlu, Catharina Andreasson, Charles Chuah, et al.
Blood|December 18, 2012
Significant weight gain in patients with chronic myeloid leukemia after imatinib therapyElvis Aduwa, Richard Szydlo, David Marin, et al.
Leukemia Research|April 17, 2007
Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantationJolanta B Perz, David Marin, Richard M Szydlo, et al.
British Journal of Haematology|July 25, 2003
Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal personsMyrtle Y Gordon, Stephen B Marley, Jane F Apperley, et al.
Frontiers in Oncology|January 27, 2022
CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid LeukemiaOren Pasvolsky, May Daher, Gheath Alatrash, et al.
Leukemia Research|September 2, 2008
Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogeneticsAlistair G Reid, Valeria A De Melo, Kay Elderfield, et al.
Cancer Genetics and Cytogenetics|April 15, 2008
Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangementsValeria A S De Melo, Dragana Milojkovic, David Marin, et al.
Pageof 18

Showing results (31-40 of 179) with videos related to

Sort By:
Pageof 18
Blood|May 3, 2002
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantationEduardo Olavarria, Charles Craddock, Francesco Dazzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2023
Novel Clinical Trial Designs with Dose Optimization to Improve Long-term OutcomesPeter F Thall, Yong Zang, Andrew G Chapple, et al.
Haematologica|September 10, 2002
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerationsDavid Marin, Sarah Marktel, Marco Bua, et al.
British Journal of Haematology|April 13, 2007
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remissionJiri Pavlu, Catharina Andreasson, Charles Chuah, et al.
Blood|December 18, 2012
Significant weight gain in patients with chronic myeloid leukemia after imatinib therapyElvis Aduwa, Richard Szydlo, David Marin, et al.
Leukemia Research|April 17, 2007
Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantationJolanta B Perz, David Marin, Richard M Szydlo, et al.
British Journal of Haematology|July 25, 2003
Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal personsMyrtle Y Gordon, Stephen B Marley, Jane F Apperley, et al.
Frontiers in Oncology|January 27, 2022
CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid LeukemiaOren Pasvolsky, May Daher, Gheath Alatrash, et al.
Leukemia Research|September 2, 2008
Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogeneticsAlistair G Reid, Valeria A De Melo, Kay Elderfield, et al.
Cancer Genetics and Cytogenetics|April 15, 2008
Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangementsValeria A S De Melo, Dragana Milojkovic, David Marin, et al.
Pageof 18